🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Zoledronic acid

    Novartis Pharmaceuticals

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  2. Zoledronic acid

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  3. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  4. Zovirax 50 mg/g crema, Lipovir 50 mg/g Gel, Placebo

    Lacuna Pharma Pty Ltd

    Recurrent herpes labialis (RHL)

    phase 3 small molecule active

    1 trial

  5. a benzodiazepine drug

    Jazz Pharmaceuticals Ireland Limited

    Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  6. a compound glutamine capsule/a compound glutamine capsule simulated placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  7. aceneuramic acid extended-release (Ace-ER)

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 3 small molecule completed

    1 trial

  8. albuterol (Armstrong Albuterol HFA)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  9. albuterol HFA (Armstrong's)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  10. alprazolam, Placebo matching Staccato® alprazolam and without active substance

    Lacuna Pharma Pty Ltd

    Treatment of stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  11. amifampridine phosphate

    CATALYST PHARMACEUTICALS, INC.

    Myasthenic Syndromes, Congenital

    phase 3 small molecule completed

    1 trial

  12. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  13. balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Heart Failure and Impaired Kidney Function

    phase 3 small molecule active

    1 trial

  14. bimatoprost ophthalmic solution formulation A

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 small molecule terminated

    1 trial

  15. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  16. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  17. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Pediatrics

    phase 3 mab completed

    4 trials

  18. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  19. brivaracetam, brivaracetam, brivaracetam, brivaracetam

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  20. budesonide/formoterol 'as needed' + budesonide placebo bid

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  21. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  22. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Cardiovascular disease

    phase 3 small molecule active

    1 trial

  23. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  24. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources